SCHEMBL7712674

SCHEMBL7712674

Cc1nc2c(NC(=O)OC(C)(C)C)cccc2n1Cc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.48
BRD4 O60885 3/20 0.46
TNF P01375 2/20 0.45
KDM4E B2RXH2 2/20 0.44
NOD2 Q9HC29 1/20 0.44
NOD1 Q9Y239 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTR6 P50406 1/20 0.41
PPARG P37231 1/20 0.41
LCK P06239 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6170220 0.79 MAPT (0.55) P2RX7BRD4TNFKDM4ENOD2
SCHEMBL8597440 0.76 KDM4E (0.40) P2RX7KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL1585672 0.74 BRD4 (0.54) P2RX7BRD4KDM4ENOD2NOD1
SCHEMBL8601890 0.74 TNF (0.46) TNFKDM4ESMN1; SMN2CYP1A2CYP2C9
SCHEMBL30207788 0.71 PDK1 (0.54) KDM4EALDH1A1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3790475 0.71 PDK1 (0.54) KDM4EALDH1A1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL8603647 0.71 MEN1 (0.40) MAPTSMN1; SMN2CYP3A4LCKHTT
SCHEMBL1160053 0.71 ALOX5AP (0.49) TNFKDM4ENOD2NOD1PPARG
Hydrochloric Acid SCHEMBL8595615 0.70 MEN1 (0.39) MAPTSMN1; SMN2CYP3A4LCKHTT
SCHEMBL476879 0.70 ALDH1A1 (0.66) P2RX7KDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6369092-B1 Method for treating neoplasia by exposure to substituted benzimidazole derivatives CELL PATHWAYS, INC. 2002-04-09 US disclosed